The Ligandable Human Proteome

Bile acid receptor

Nuclear hormone receptor, ligand-binding domain

Index	Ligand Name	Structure	PDB code	ligand desolvation
1	t73	Novel natural FXR modulator with a unique binding mode	5iaw	99.88
2	9r3	FXR-LBD with HNC180 and SRC1	6a5x	99.7
3	9ld	Ligand binding to FARNESOID-X-RECEPTOR	5q0q	99.45
4	93u	FXR ligand binding domain	5yxj	99.39
5	xd4	A novel moderator XD4 for bile acid receptor	5y44	99.33
6	9m7	Ligand binding to FARNESOID-X-RECEPTOR	5q11	99.16
7	33y	A structure of FXR/RXR	5z12	99.16
8	ook	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid	3ook	99.02
9	33y	Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Receptor (FXR)	3fli	99
10	9n4	Ligand binding to FARNESOID-X-RECEPTOR	5q1a	98.83
11	fez	A unique binding model of FXR LBD with feroline	5ick	98.8
12	9n7	Ligand binding to FARNESOID-X-RECEPTOR	5q1b	98.8
13	xx9	Structural basis for small molecule NDB as a selective antagonist of FXR	4oiv	98.8
14	9nj	Ligand binding to FARNESOID-X-RECEPTOR	5q1f	98.75
15	9np	Ligand binding to FARNESOID-X-RECEPTOR	5q1h	98.75
16	9lg	Ligand binding to FARNESOID-X-RECEPTOR	5q0r	98.71
17	9lv	Ligand binding to FARNESOID-X-RECEPTOR	5q0w	98.68
18	9lp	Ligand binding to FARNESOID-X-RECEPTOR	5q0u	98.68
19	olf	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid	3olf	98.67
20	niw	A ligand M binding to FXR	5yxl	98.65
21	9n1	Ligand binding to FARNESOID-X-RECEPTOR	5q19	98.65
22	omm	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid	3omm	98.64
23	9o1	Ligand binding to FARNESOID-X-RECEPTOR	5q1i	98.61
24	9la	Ligand binding to FARNESOID-X-RECEPTOR	5q0p	98.61
25	9l7	Ligand binding to FARNESOID-X-RECEPTOR	5q0o	98.59
26	9ma	Ligand binding to FARNESOID-X-RECEPTOR	5q12	98.52
27	9ky	Ligand binding to FARNESOID-X-RECEPTOR	5q0l	98.51
28	9kv	Ligand binding to FARNESOID-X-RECEPTOR	5q0j	98.5
29	9ms	Ligand binding to FARNESOID-X-RECEPTOR	5q16	98.48
30	9md	Ligand binding to FARNESOID-X-RECEPTOR	5q13	98.47
31	9mm	Ligand binding to FARNESOID-X-RECEPTOR	5q14	98.47
32	9mp	Ligand binding to FARNESOID-X-RECEPTOR	5q15	98.46
33	9lj	Ligand binding to FARNESOID-X-RECEPTOR	5q0s	98.43
34	9ng	Ligand binding to FARNESOID-X-RECEPTOR	5q1e	98.42
35	9m4	Ligand binding to FARNESOID-X-RECEPTOR	5q10	98.37
36	9ls	Ligand binding to FARNESOID-X-RECEPTOR	5q0v	98.24
37	9ly	Ligand binding to FARNESOID-X-RECEPTOR	5q0y	98.23
38	9nm	Ligand binding to FARNESOID-X-RECEPTOR	5q1g	98.21
39	9na	Ligand binding to FARNESOID-X-RECEPTOR	5q1c	98.1
40	9nd	Ligand binding to FARNESOID-X-RECEPTOR	5q1d	98.1
41	omk	Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide	3omk	98.05
42	oof	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid	3oof	98.04
43	oki	Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide	3oki	97.98
44	9mv	Ligand binding to FARNESOID-X-RECEPTOR	5q17	97.92
45	9my	Ligand binding to FARNESOID-X-RECEPTOR	5q18	97.88
46	89p	FXR bound to a quinolinecarboxylic acid	3p89	97.8
47	9l4	Ligand binding to FARNESOID-X-RECEPTOR	5q0n	97.78
48	59g	FXR with SRC1 and GSK359	3rut	97.66
49	d5h	Crystal structure of human FXR in complex with a functional drug ligand	5y1j	97.57
50	37g	FXR with SRC1 and GSK237	3ruu	97.5
51	fex	A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR	1osh	97.21
52	muf	Structure of human FXR in complex with MFA-1 and co-activator peptide	3bej	97.09
53	064	FXR with SRC1 and GW4064	3dct	96.86
54	82x	FXR with SRC1 and GSK826	3hc5	96.66
55	9lm	Ligand binding to FARNESOID-X-RECEPTOR	5q0t	96.61
56	31d	FXR with DM175 and NCoA-2 peptide	4qe8	96.06
57	o62	FXR with SRC1 and GSK8062	3dcu	95.95
58	93r	A ligand F binding to FXR	5yxd	95.53
59	chc	Structural Basis for 3-deoxy-CDCA Binding and Activation of FXR	1ot7	95.52
60	9r0	Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1	6a5y	95.38
61	p88	FXR bound to isoquinolinecarboxylic acid	3p88	95.26
62	chc	STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR	1osv	95.17
63	jn3	FXR with CDCA and NCoA-2 peptide	4qe6	94.76
64	9r0	FXR-LBD with HNC143 and SRC1	6a5w	94.45
65	jn3	Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide and CDCA	6hl1	94.4
66	643	Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist	3fxv	93.03
67	643	Ligand binding to FARNESOID-X-RECEPTOR	5q0x	92.6
68	9r3	Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1	6a5z	91.51
69	9l1	Ligand binding to FARNESOID-X-RECEPTOR	5q0m	89.82
70	635	Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound	3l1b	81.7
71	okh	Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid	3okh	70.09